349 related articles for article (PubMed ID: 14769338)
1. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
2. A scintillation proximity assay for poly(ADP-ribose) polymerase.
Cheung A; Zhang J
Anal Biochem; 2000 Jun; 282(1):24-8. PubMed ID: 10860495
[TBL] [Abstract][Full Text] [Related]
3. A FlashPlate assay for the identification of PARP-1 inhibitors.
Dillon KJ; Smith GC; Martin NM
J Biomol Screen; 2003 Jun; 8(3):347-52. PubMed ID: 12857389
[TBL] [Abstract][Full Text] [Related]
4. Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
Pogrebniak A; Schemainda I; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2003 Oct; 8(10):438-50. PubMed ID: 14594650
[TBL] [Abstract][Full Text] [Related]
5. A nonradiometric, high-throughput assay for poly(ADP-ribose) glycohydrolase (PARG): application to inhibitor identification and evaluation.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Oct; 333(2):256-64. PubMed ID: 15450800
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of poly(ADP-ribose) polymerase (PARP) influences the mode of sulfur mustard (SM)-induced cell death in HaCaT cells.
Kehe K; Raithel K; Kreppel H; Jochum M; Worek F; Thiermann H
Arch Toxicol; 2008 Jul; 82(7):461-70. PubMed ID: 18046540
[TBL] [Abstract][Full Text] [Related]
7. Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
Lee S; Koo HN; Lee BH
Methods Find Exp Clin Pharmacol; 2005 Nov; 27(9):617-22. PubMed ID: 16357945
[TBL] [Abstract][Full Text] [Related]
8. An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications.
Decker P; Miranda EA; de Murcia G; Muller S
Clin Cancer Res; 1999 May; 5(5):1169-72. PubMed ID: 10353753
[TBL] [Abstract][Full Text] [Related]
9. Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP-ribose) metabolism.
Bakondi E; Bai P; Erdélyi K; Szabó C; Gergely P; Virág L
Exp Dermatol; 2004 Mar; 13(3):170-8. PubMed ID: 14987257
[TBL] [Abstract][Full Text] [Related]
10. Differential contribution of poly(ADP-ribose)polymerase-1 and -2 (PARP-1 and -2) to the poly(ADP-ribosyl)ation reaction in rat primary spermatocytes.
Tramontano F; Malanga M; Quesada P
Mol Hum Reprod; 2007 Nov; 13(11):821-8. PubMed ID: 17766683
[TBL] [Abstract][Full Text] [Related]
11. Chain length analysis of ADP-ribose polymers generated by poly(ADP-ribose) polymerase (PARP) as a function of beta-NAD+ and enzyme concentrations.
Mendoza-Alvarez H; Chavez-Bueno S; Alvarez-Gonzalez R
IUBMB Life; 2000 Aug; 50(2):145-9. PubMed ID: 11185961
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADP-ribose).
Okita N; Ashizawa D; Ohta R; Abe H; Tanuma S
Biochem Biophys Res Commun; 2010 Feb; 392(4):485-9. PubMed ID: 20079708
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of poly(ADP-ribose) polymerase enhances growth rates of ataxia telangiectasia cells.
Marecki JC; McCord JM
Arch Biochem Biophys; 2002 Jun; 402(2):227-34. PubMed ID: 12051667
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
15. Metformin suppresses high glucose-induced poly(adenosine diphosphate-ribose) polymerase overactivation in aortic endothelial cells.
Mahrouf-Yorgov M; Marie N; Borderie D; Djelidi R; Bonnefont-Rousselot D; Legrand A; Beaudeux JL; Peynet J
Metabolism; 2009 Apr; 58(4):525-33. PubMed ID: 19303974
[TBL] [Abstract][Full Text] [Related]
16. Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay.
Gerö D; Módis K; Nagy N; Szoleczky P; Tóth ZD; Dormán G; Szabó C
Int J Mol Med; 2007 Nov; 20(5):749-61. PubMed ID: 17912470
[TBL] [Abstract][Full Text] [Related]
17. Neither energy collapse nor transcription underlie in vitro neurotoxicity of poly(ADP-ribose) polymerase hyper-activation.
Fossati S; Cipriani G; Moroni F; Chiarugi A
Neurochem Int; 2007 Jan; 50(1):203-10. PubMed ID: 17052800
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
19. Different basal NAD levels determine opposite effects of poly(ADP-ribosyl)polymerase inhibitors on H2O2-induced apoptosis.
Coppola S; Nosseri C; Maresca V; Ghibelli L
Exp Cell Res; 1995 Dec; 221(2):462-9. PubMed ID: 7493646
[TBL] [Abstract][Full Text] [Related]
20. NAD(+) consumption in carcinogen-treated hamster cells overexpressing a dominant negative mutant of poly(ADP-ribose) polymerase.
Küpper JH; Müller M; Wolf I
Biochem Biophys Res Commun; 1999 Nov; 265(2):525-9. PubMed ID: 10558902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
